$Novavax(NVAX)$ The Serum Institute is expanding its Novavax production capacity by a billion doses. Novavax is buying these on a per dose basis, so it keeps all of the profits.
Novavax achieved its goal of 100M doses per month in Q3, and is on track to achieve its goal of 150M by December. This indicates 600M doses in 2021.
9 EUA filings have been done, covering most of the world. The vaccine has been approved by the 4th largest country, Indonesia, and many more approvals are expected soon.
The UK has already inspected and certified the SII factories, indicating it will likely give approval soon. Most countries in the world accept UK approvals.
With 2.1 billion in orders and likely 2022 revenues of $22B , this is highly undervalued and one of the strongest buys I've seen in a few years.